Project Details
Description
The primary objective is to evaluate genetically modified epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model.
Specific goals: Identification of specific, genetically modified antigens of hepatocellular carcinoma using new generation sequencing and evaluation of specific T cell response in vitro, before and after therapy.
Evaluation of genetically altered epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model.
Identification of protein-specific, genetically modified cell-surface specific full-length hepatocellular carcinoma cells and immune evaluation in vivo.
The main activities:
Identification of mutant neoantigens in liver carcinoma of different aetiology and assessment of in vitro T cell specific response after treatment with cell cycle inhibitors.
Identification of selected mutant epitopes in vivo using HLA transgenic mice and their therapeutic effect in a HCC-PDX animal model.
Specific goals: Identification of specific, genetically modified antigens of hepatocellular carcinoma using new generation sequencing and evaluation of specific T cell response in vitro, before and after therapy.
Evaluation of genetically altered epitope immunogenicity in HLA transgenic mice in vivo and their therapeutic effect in the HCC-PDX animal model.
Identification of protein-specific, genetically modified cell-surface specific full-length hepatocellular carcinoma cells and immune evaluation in vivo.
The main activities:
Identification of mutant neoantigens in liver carcinoma of different aetiology and assessment of in vitro T cell specific response after treatment with cell cycle inhibitors.
Identification of selected mutant epitopes in vivo using HLA transgenic mice and their therapeutic effect in a HCC-PDX animal model.
| Acronym | HEPAMUT |
|---|---|
| Status | Finished |
| Effective start/end date | 20/02/17 → 19/02/20 |
| Links | https://www.rsu.lv/en/project/mutated-neo-antigens-hepatocellular-carcinoma-hepamut http://www.hepamut.eu/ |
Collaborative partners
- Rīga Stradiņš University
- IRCCS Istituto nazionale tumori Fondazione Giovanni Pascale - Napoli (Project partner) (lead)
- Nantes Université (Project partner)
- University Hospital of Navarra (Project partner)
- KU Leuven (Project partner)
- IRCCS Ospedale San Raffaele (Project partner)
- Competence Centre of Cancer Research (Project partner)
Total Funding
- European Commission: €1,109,900.00
Keywords
- liver cancer
- mutated human tumor antigenic targets
- omics approaches
- immunulogical validation ex vivo and in vivo
- development of HCC-PDX animal models
- immune checkpoint inhibit
Field of Science
- 3.3 Health sciences
Smart Specialization Area
- Biomedicine, medical technologies and biotechnology
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.